November 9, 2022- Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
Contact details
-
- Sarah Wakefield
-
KBI Biopharma Company Inquiries
SVP, Corporate Communications - swakefield@kbibiopharma.com
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Copy link
https://news.jsrlifesciences.com/220103-tim-lowery-appointed-interim-ceo-of-kbi-and-selexisRelated topics
Related news
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract man...
KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and M...
KBI Biopharma, Inc. (KBI Biopharma), a JSR Life Sciences company, today announced the launch of SUREmAb™, an offering built on the robustness of KBI’s SUREtechnology Platform, that allows for optim...
KBI Biopharma Continues to Strengthen Leadership and Expertise With Key Executive Appointments
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced four recent executive appointments to continue its momentum and vision of becoming a next-generation CDMO.
KBI Biopharma Unveils KBI PUREplatform™, a Game-Changing Microbial Expression Offering to Redefine Biopharmaceutical ...
Platform leverages proprietary PUREcoli™ strain and cutting-edge screening packages for unmatched efficiencies and optimized production processes
JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organiz...
KBI’s new model will enhance operational efficiencies, drive strategic clarity, and accelerate innovation for global biopharma customers